Table 1.

Clinical and hematologic characteristics at diagnosis of the MDS-Eos, MDS-Bas, and MDS−/− patients

MDS-Eos,
n = 36
MDS-Bas,
n = 34
MDS−/−,
n = 229
P
FAB (%)    < .05 
 RA 10 (28) 2 (6) 82 (36)  
 RARS 0 (0) 2 (6) 13 (6)  
 RAEB 12 (33) 19 (56) 68 (30)  
 RAEBt 10 (28) 8 (23) 47 (20)  
 CMML 4 (11) 3 (9) 19 (8)  
Sex    NS 
 Male 29 26 150  
 Female  7  8  79  
Median age, y
(range) 
68 (23-87) 64.5 (25-87) 68 (15-93) NS 
Peripheral blood
(range) 
    
 Hb, g/dL 6.9 (3.1-11.8) 7.4 (4.2-11.4) 8.0 (3.2-13.6)* < .05 
 PMN, × 109/L 1.9 (0.1-33.3) 2.0 (0.2-33.3) 1.3 (0.1-39.2) NS 
 Eos, × 109/L 0.15 (0-2.1) 0.05 (0-2.1) 0.02 (0-1.2) < .01 
 Bas, × 109/L 0.02 (0-0.36) 0.06 (0-0.84)1-153 0.01 (0-0.89) < .01 
 Plt, × 109/L 84 (12-1400) 84 (1.0-1400) 60 (0.5-1240) NS 
MDS-Eos,
n = 36
MDS-Bas,
n = 34
MDS−/−,
n = 229
P
FAB (%)    < .05 
 RA 10 (28) 2 (6) 82 (36)  
 RARS 0 (0) 2 (6) 13 (6)  
 RAEB 12 (33) 19 (56) 68 (30)  
 RAEBt 10 (28) 8 (23) 47 (20)  
 CMML 4 (11) 3 (9) 19 (8)  
Sex    NS 
 Male 29 26 150  
 Female  7  8  79  
Median age, y
(range) 
68 (23-87) 64.5 (25-87) 68 (15-93) NS 
Peripheral blood
(range) 
    
 Hb, g/dL 6.9 (3.1-11.8) 7.4 (4.2-11.4) 8.0 (3.2-13.6)* < .05 
 PMN, × 109/L 1.9 (0.1-33.3) 2.0 (0.2-33.3) 1.3 (0.1-39.2) NS 
 Eos, × 109/L 0.15 (0-2.1) 0.05 (0-2.1) 0.02 (0-1.2) < .01 
 Bas, × 109/L 0.02 (0-0.36) 0.06 (0-0.84)1-153 0.01 (0-0.89) < .01 
 Plt, × 109/L 84 (12-1400) 84 (1.0-1400) 60 (0.5-1240) NS 

NS indicates not significant; PMN, polymorphonuclear neutrophil; and Plt, platelet.

*

Hb concentration of the MDS−/− group is significantly higher than that of the MDS-Eos group.

Circulating eosinophil counts were significantly higher in MDS-Eos compared with those in MDS-Bas and MDS−/−.

Circulating eosinophil counts were significantly higher in MDS-Bas compared with those in MDS−/−.

F1-153

Circulating basophil counts were significantly higher in MDS-Bas compared with those in MDS-Eos and MDS−/−.